IMS 2024 | Frontline systemic treatment outcomes in patients with POEMS syndrome
Oliver Tomkins
• 27 Sep 2024
Oliver Tomkins, BMBS, BMedSci, DTMH, MRCP(UK), FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, provides an insight into the frontline systemic treatment outcomes in transplant-eligible and transplant-ineligible patients with POEMS syndrome, highlighting some of the key findings from a registry study. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
